We are live on ! Find out more
SUPN icon

Supernus Pharmaceuticals
SUPN

213 hedge funds and large institutions have $685M invested in Supernus Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 83 increasing their positions, 82 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

140% more call options, than puts

Call options by funds: $3.77M | Put options by funds: $1.57M

21% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 28

13% more capital invested

Capital invested by funds: $604M → $685M (+$80.6M)

2% more funds holding

Funds holding: 209 → 213 (+4)

1% more repeat investments, than reductions

Existing positions increased: 83 | Existing positions reduced: 82

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

Holders
213
Holders Change
+4
Holders Change %
+1.91%
% of All Funds
5.68%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
34
Increased
83
Reduced
82
Closed
28
Calls
$3.77M
Puts
$1.57M
Net Calls
+$2.2M
Net Calls Change
+$2.18M

Top Buyers

1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$12.3M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$10.7M
3
Bank of New York Mellon
Bank of New York Mellon
New York
+$8.18M
4
RIM
Ranger Investment Management
Texas
+$5.55M
5
GIM
Granahan Investment Management
Massachusetts
+$5.09M

Top Sellers

1
KCM
Kornitzer Capital Management
Kansas
-$6.06M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$5.67M
3
Invesco
Invesco
Georgia
-$5.35M
4
MRM
Michael R. Murphy
-$4.95M
5
State Street
State Street
Massachusetts
-$4.79M
Name Holding Trade Value Shares
Change 		Change in
Stake
SGAM
51
Smith Group Asset Management
Texas
$3.56M +$3.03M +232,380 +19,173%
CM
52
Castleark Management
Illinois
$3.44M -$437K -33,510 -13%
GC
53
Guggenheim Capital
Illinois
$3.43M -$668K -51,206 -19%
BC
54
Bruce & Co
Illinois
$3.42M -$391K -30,000 -12%
PA
55
Perceptive Advisors
New York
$3.05M +$2.61M +200,000 New
ISL
56
Ingalls & Snyder LLC
New York
$2.94M +$124K +9,500 +5%
PPA
57
Parametric Portfolio Associates
Washington
$2.94M +$2.02M +154,929 +411%
TCIM
58
TIAA CREF Investment Management
New York
$2.91M +$673K +51,580 +37%
JP Morgan Chase
59
JP Morgan Chase
New York
$2.87M +$1.11K +85 +0%
AQR Capital Management
60
AQR Capital Management
Connecticut
$2.61M +$323K +24,740 +17%
SI
61
Scout Investments
Missouri
$2.51M +$519K +39,800 +32%
Millennium Management
62
Millennium Management
New York
$2.32M -$778K -59,618 -28%
American Century Companies
63
American Century Companies
Missouri
$2.29M +$1.96M +150,172 New
Wellington Management Group
64
Wellington Management Group
Massachusetts
$2.24M -$1.14M -87,669 -37%
BGIM
65
Brandywine Global Investment Management
Pennsylvania
$2.22M -$285K -21,845 -13%
SEI Investments
66
SEI Investments
Pennsylvania
$2.17M -$912K -69,926 -33%
BIM
67
BlackRock Investment Management
Delaware
$2.12M -$126K -9,648 -6%
NIP
68
Nicholas Investment Partners
California
$1.99M +$1.7M +130,523 New
Charles Schwab
69
Charles Schwab
California
$1.96M -$2.41M -184,455 -59%
Macquarie Group
70
Macquarie Group
Australia
$1.96M +$1.68M +128,400 New
OM
71
Opaleye Management
Massachusetts
$1.91M -$3.85M -295,000 -70%
PC
72
Polar Capital
United Kingdom
$1.86M +$210K +16,065 +15%
PI
73
Putnam Investments
Massachusetts
$1.77M +$500K +38,284 +49%
FSA
74
Franklin Street Advisors
North Carolina
$1.75M -$131K -10,075 -8%
Stifel Financial
75
Stifel Financial
Missouri
$1.71M -$208K -15,918 -12%
1 2
3
4 5

SUPN Hedge Fund Activity: Q1 2016 in Review

213 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q1 2016, worth a combined $685M — up 13% from $604M a quarter earlier.

Buyers outnumbered sellers: 34 funds opened new SUPN positions and 28 closed out — a net gain of 6 holders — while 83 added to existing stakes and 82 trimmed.

The largest buyer was Point72 Asset Management, opening a new position worth an estimated $12.3M. The largest seller was Kornitzer Capital Management, cutting an estimated $6.06M.

  • 213 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q1 2016, up from 209 in Q4 2015.
  • Funds reported $685M of Supernus Pharmaceuticals stock for Q1 2016, up 13% quarter-over-quarter.
  • 34 funds opened new Supernus Pharmaceuticals positions in Q1 2016 and 28 closed out, a net change of +6 holders.
  • The largest Supernus Pharmaceuticals buyer in Q1 2016 was Point72 Asset Management, an estimated $12.3M added.
  • The largest Supernus Pharmaceuticals seller in Q1 2016 was Kornitzer Capital Management, an estimated $6.06M sold.

Based on aggregated 13F filings for Q1 2016.